Myriad Genetics validates polygenic risk score for breast cancer
Category: #health  By Mateen Dalal  Date: 2019-12-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Myriad Genetics validates polygenic risk score for breast cancer

Myriad Genetics, Inc., a company focused on precision medicine and molecular diagnostics, has reportedly presented the result of a new validation study of its polygenic risk score (PRS) for breast cancer at the 2019 San Antonio Breast Cancer Symposium in San Antonio, Texas. 

The result showed that the PRS substantially enhances the accuracy and precision of breast cancer risk evaluations for women of European ancestry with PV (pathogenic variants) in moderate- and high-penetrance breast cancer genes.

Jerry Lanchbury, Ph.D., Chief Scientific Officer, Myriad Genetics, said that the company’s goal is to help women in understanding the risk of breast cancer so that they can take proactive steps to healthier and longer lives. Females who have a family record of breast cancer should think about hereditary cancer testing with the myRisk Hereditary Cancer test, said Lanchbury.

Moreover, the study showed that for women, who are tested positive for a mutation in one of the five breast cancer genes, own added genetic factors termed single nucleotide polymorphisms (SNPs) that can further aid the lifelong risk of breast cancer.

As for Elisha Hughes, Ph.D., Lead Investigator and Director of Bioinformatics at Myriad Genetics, said that these findings signal that the company has the potential to considerably enhance the precision of hereditary cancer risk evaluation for females who test positive for mutations in intermediate to high-risk breast cancer genes.

Hughes added that this additional genetic information could help clinicians to accurately and precisely predict breast cancer risk and offer the best care for their patients in the future.

Sources further inform that Myriad Genetics, following this announcement, plans to publish these new data in a peer reviewed medical journal and make PRS available for U.S. women of European ancestry, who are tested positive for mutations in breast cancer genes.

Currently, the PRS is available as part of the Myriad myRisk® Hereditary Cancer improved with riskScore® for women of European ancestry who exam negative for pathogenic mutations in breast cancer genes. 
 

Source Credit - https://myriad.com/investors/news-release/news-release-detail/?newsItemId=20921

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Snapchat announces the launch of in-app TikTok competitor Spotlight
Snapchat announces the launch of in-app TikTok competitor Spotlight
By Mateen Dalal

Snapchat, an American multimedia messaging platform, has reportedly launched a new section of its application called Spotlight. The new feature will offer surface video content and will allow the company to compete with Chinese video sharing platform...

Google Pay updated to become an all-in-one-bank ahead of Plex launch
Google Pay updated to become an all-in-one-bank ahead of Plex launch
By Mateen Dalal

Google’s digital wallet and online payment system Google Pay has reportedly been updated with a bunch of new features, UI, and a logo. Sources with relevant information claimed that these changes are a result of huge upscaling of Google Pay as ...

Alibaba generates revenues worth USD 74 billion in Singles Day sale
Alibaba generates revenues worth USD 74 billion in Singles Day sale
By Mateen Dalal

Alibaba, a Chinese multinational technology company, has reportedly generated sales worth USD 74 billion in its post COVID-19 Singles’ Day shopping extravaganza. The recent development follows the company recently witnessing a 10% decline in it...